Implanet concludes its partnership with Sanyou Medical – 09/19/2022 at 18:23


(AOF) – Implanet, a medical technology company specializing in spinal implants, announced that all the conditions precedent relating to the partnership project with Sanyou Medical have now been fulfilled. Implanet’s Board of Directors will meet shortly to decide on the precise terms and the final timetable for the capital increase operation.

Ludovic Lastennet, CEO of Implanet, explains: “The commercial, technological and financial partnership concluded with Sanyou Medical will now deploy its full potential. Thanks to the lifting of these conditions precedent, the distribution agreement and the technological synergies negotiated will be able to be implemented, as well as our capital increase project, which will be open to all our shareholders and should take place before October 31, 2022.”

David Fan, co-founder and Deputy CEO of Sanyou Medical, adds: “Following the lifting of the last conditions precedent, we confirm our desire to invest in Implanet the amount of 5 million euros, in accordance with the provisions of the agreement investment agreement signed in June 2022. We are confident in the ability of the two teams to combine, in the near future, their technical and commercial skills in order to build a new key player in spinal surgery.”

AOF – LEARN MORE

An inevitable race for new blockbusters

The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.



Source link -86